For patients with lymphoma, the dose and frequency of HBV, sex, Ann Arbor stage, and ibrutinib as part of the chemotherapy regimen are independent factors that affect the impact of the vaccine.
Two studies on hepatitis A and hepatitis B vaccination highlight opportunities to improve coverage of ≥2 doses of hepatitis A vaccine in children and hepatitis B vaccine series completion in adults.
Direct-acting antiviral agents for treatment of hepatitis C virus may have higher sustained virologic responses in people coinfected with hepatitis B and hepatitis C viruses.
Optimized, commercial enzyme immunoassays may be able to diagnose hepatitis B virus using oral fluid samples.
Patients with HIV and HBV coinfection who received tenofovir-based ART rarely demonstrated a detectable HBV DNA at 8-year follow-up.
Data published in Clinical Infectious Diseases revealed that by 2014, less than one-third of individuals aged 18 to 49 years who were at risk for hepatitis B virus (HBV) exhibited hepatitis B surface antibody levels indicative of protection (anti-HBs >10 mIU/mL). Data from the 2003 to 2014 National Health and Nutrition Examination Surveys were used…
The United States Preventative Service Task Force has issued a statement that reaffirms its 2009 recommendations for screening pregnant women for hepatitis B virus.
The novel method of lateral flow immunoassay may be a cost-effective way to identify patients with chronic hepatitis B virus infection.
Fibronectin may be a potential marker for hepatitis B surface antigen seroclearance.
Certain characteristics and HIV-related factors may help predict whether certain demographics of people with HIV will have an optimal response to reinforced hepatitis B virus vaccination.
